• New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
• Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
• Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.

[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.

Holzkirchen, August 31, 2016 – New data just …

• Erelzi is approved for all indications included in the reference product’s label
   
• Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
   
• Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars

Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …

• First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.
• Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).
• Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.

Holzkirchen, August 9, 2016 – Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access …